157 related articles for article (PubMed ID: 6163740)
1. Cholecystokinin (pancreozymin). Synthesis and properties of the N alpha-acetyl-derivative of cholecystokinin 27-33.
Bodanszky M; Tolle JC; Gardner JD; Walker MD; Mutt V
Int J Pept Protein Res; 1980 Nov; 16(5):402-11. PubMed ID: 6163740
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin (pancreozymin). 4. Synthesis and properties of a biologically active analogue of the C-terminal heptapeptide with epsilon-hydroxynorleucine sulfate replacing tyrosine sulfate.
Bodanszky M; Martinez J; Priestley GP; Gardner JD; Mutt V
J Med Chem; 1978 Oct; 21(10):1030-5. PubMed ID: 722712
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and some pharmacological properties of Z-Tyr(SO3H)-Met-Gly-Trp-Met-Asp(Phe-NH2)-OH, a 32-beta-aspartyl analogue of cholecystokinin (pancreozymin) 27-33.
Martinez J; Winternitz F; Bodanszky M; Gardner JD; Walker MD; Mutt V
J Med Chem; 1982 May; 25(5):589-93. PubMed ID: 6177857
[TBL] [Abstract][Full Text] [Related]
4. N-terminal fragments of CCK-(26-33) as cholecystokinin receptor antagonists in guinea pig pancreatic acini.
Gardner JD; Knight M; Sutliff VE; Jensen RT
Am J Physiol; 1985 Jan; 248(1 Pt 1):G98-102. PubMed ID: 2578257
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin (pancreozymin). 5. Hormonally active desamino derivative of Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2.
Bodanszky M; Martinez J; Walker M; Gardner JD; Mutt V
J Med Chem; 1980 Jan; 23(1):82-5. PubMed ID: 6153722
[No Abstract] [Full Text] [Related]
6. Effect of cholecystokinin variant (CCK39) on dispersed acinar cells from guinea pig pancreas.
Sjodin L; Gardner JD
Gastroenterology; 1977 Nov; 73(5):1015-8. PubMed ID: 198332
[TBL] [Abstract][Full Text] [Related]
7. Bioactivity of cholecystokinin analogues: CCK-8 is not more potent than CCK-33.
Solomon TE; Yamada T; Elashoff J; Wood J; Beglinger C
Am J Physiol; 1984 Jul; 247(1 Pt 1):G105-11. PubMed ID: 6204542
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
[TBL] [Abstract][Full Text] [Related]
9. [Studies on the total synthesis of cholecystokinin-pancreozymin. Synthesis of the suitably protected fragment corresponding to the sequence 24--33 (author's transl)].
Wünsch E; Moroder L; Wilschowitz L; Göhring W; Scharf R; Gardner JD
Hoppe Seylers Z Physiol Chem; 1981 Feb; 362(2):143-52. PubMed ID: 7216168
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin.
Rodriguez M; Galas MC; Lignon MF; Mendre C; Laur J; Aumelas A; Martinez J
J Med Chem; 1989 Oct; 32(10):2331-9. PubMed ID: 2477546
[TBL] [Abstract][Full Text] [Related]
11. Suc-Tyr(SE)-Met-Gly-Trp-Met-Asp-beta-phenethylamide(410): a competitive antagonist of cholecystokinin-induced contractions in smooth muscles in vitro.
Rakovska A; Henklein P; Milenov K; Nieber K; Oehme P
Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):429-35. PubMed ID: 3683016
[TBL] [Abstract][Full Text] [Related]
12. 2-Phenylethyl ester and 2-phenylethyl amide derivative analogues of the C-terminal hepta- and octapeptide of cholecystokinin.
Fulcrand P; Rodriguez M; Galas MC; Lignon MF; Laur J; Aumelas A; Martinez J
Int J Pept Protein Res; 1988 Nov; 32(5):384-95. PubMed ID: 2463231
[TBL] [Abstract][Full Text] [Related]
13. [Cholecystokinin-pancreozymin synthesis. Synthesis of [28-threonine,31-norleucine]- and [28-threonine,31-leucine]cholecystokinin-pancreozymin-(25-33)-nonapeptide].
Moroder L; Wilschowitz L; Gemeiner M; Göhring W; Knof S; Scharf R; Thamm P; Gardner JD; Solomon TE; Wünsch E
Hoppe Seylers Z Physiol Chem; 1981 Jul; 362(7):929-42. PubMed ID: 7275014
[TBL] [Abstract][Full Text] [Related]
14. Role of sulfate ester in influencing biologic activity of cholecystokinin-related peptides.
Vinayek R; Jensen RT; Gardner JD
Am J Physiol; 1987 Feb; 252(2 Pt 1):G178-81. PubMed ID: 2435164
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin (pancreozymin). 3. Synthesis and properties of an analogue of the C-terminal heptapeptide with serine sulfate replacing tyrosine sulfate.
Bodanszky M; Natarajan S; Hahne W; Gardner JD
J Med Chem; 1977 Aug; 20(8):1047-50. PubMed ID: 894673
[TBL] [Abstract][Full Text] [Related]
16. The importance of the amino acid in position 27 of cholecystokinin in determining its biological activity on pancreatic acini.
Gardner JD; Walker MD; Martinez J; Priestly GP; Natarajan S; Bodanszky M
Biochim Biophys Acta; 1980 Jul; 630(3):323-9. PubMed ID: 6156709
[TBL] [Abstract][Full Text] [Related]
17. In-vitro bioassays for cholecystokinin.
Sjödin L; Nederman T; Olsson PA; Viitanen E
J Pharm Pharmacol; 1989 Jun; 41(6):402-6. PubMed ID: 2476543
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity.
Galas MC; Lignon MF; Rodriguez M; Mendre C; Fulcrand P; Laur J; Martinez J
Am J Physiol; 1988 Feb; 254(2 Pt 1):G176-82. PubMed ID: 2450468
[TBL] [Abstract][Full Text] [Related]
19. Sequence variation outside the "active" region of dog and rabbit cholecystokinin-58 results in bioactivity differences.
Reeve JR; Liddle RA; Shively JE; Lee TD; Keire DA; Chew P; Vigna SR
Pancreas; 2006 Apr; 32(3):306-13. PubMed ID: 16628087
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinic activity of N alpha-hydroxysulfonyl-[Nle28,31]CCK26-33 analogues modified at the C-terminal residue.
Sugg EE; Serra M; Shook JE; Yamamura HI; Burks TF; Korc M; Hruby VJ
Int J Pept Protein Res; 1988 Jun; 31(6):514-9. PubMed ID: 2457563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
